New Haven antibiotics startup BioRelix Inc. has drawn another $2.5 million from investors, including $270,000 more from the state of Connecticut.
Connecticut Innovations Inc., the state's technology-investment arm in Rocky Hill, announced Tuesday a follow-on investment of $269,160 in BioRelix through its Eli Whitney Fund.
CI first invested $500,000 in BioRelix last December, along with a consortium of investors consisting of CHL Medical Partners, Novartis Bioventures, New Leaf Ventures, Aisling Capital, Elm Street Ventures, Alexandria Equities, that invested another $3.75 million.
It also raised $3.6 million from private investors last September.
BioRelix is developing antibiotics using bits of a germ's own ribonucleic acid (RNA) messenger gene against it.